Impact of a Clinical Genomics Program on Trial Accrual for Targeted Treatments: Practical Approach Overcoming Barriers to Accrual for Underserved Patients This novel algorithm will facilitate research ...

The approval also covers Keytruda SC, known in the US as Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph).

Ovarian cystic neoplasms are ovarian tumors that have cyst-like qualities. They can include epithelial ovarian tumors and germ cell tumors called teratomas. Ovarian cystic neoplasms can be benign, ...

Merck’s Keytruda plus paclitaxel ± bevacizumab gets EU approval to treat adults with PD-L1 platinum-resistant recurrent ovarian carcinoma who have received one or two prior systemic treatment regimens ...

Neoadjuvant chemotherapy (NACT) followed by interval cytoreductive surgery (ICS) has become the predominant treatment for advanced epithelial ovarian cancer (EOC), overtaking primary cytoreductive ...

FDA authorization covers platinum-resistant disease after 1–3 prior lines, with mandatory prior bevacizumab exposure, ...

Patients with stage IV epithelial ovarian cancer (OC) treated with surgery and chemotherapy exhibit the best prognosis. To do so, they analyzed patients with stage IV epithelial OC within the ...

Ovarian cancer remains the deadliest gynecologic cancer, largely because it is rarely found early. Symptoms are often vague, ...

Impact of a Clinical Genomics Program on Trial Accrual for Targeted Treatments: Practical Approach Overcoming Barriers to Accrual for Underserved Patients We created a five-step algorithm on the basis ...